Jason D. Wright, MD

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses clinical trial designs in ovarian cancer.

Many patients with ovarian cancer receive a variety of off-label therapies. Nevertheless, overall survival has improved.

The ovarian cancer community must weigh the pros and cons of a sound trial design with its application in the real world.

Progression-free survival has its limitations but is probably the most reasonable trial endpoint.

Videos

Jason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.

Trial Designs in Ovarian Cancer

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

PFS is the most commonly used endpoint for ovarian cancer clinical trials.

PFS is relatively easily measured and can be measured in a timely fashion.

However, PFS does not always correlate with overall survival.

Olaparib was recently approved for ovarian cancer.

Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

Jason D. Wright, MD | Authors

Articles

Trial Designs in Ovarian Cancer

PFS as an Endpoint in Ovarian Cancer Clinical Trials